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Association of Coronary Artery Calcium With Long-term,
Cause-Specific Mortality Among Young Adults
Michael D. Miedema, MD, MPH; Zeina A. Dardari, MS; Khurram Nasir, MD; Ron Blankstein, MD; Thomas Knickelbine, MD; Sandra Oberembt, PA-C; Leslee Shaw, PhD;
John Rumberger, MD, PhD; Erin D. Michos, MD, MHS; Alan Rozanski, MD; Daniel S. Berman, MD; Matthew J. Budoff, MD; Michael J. Blaha, MD, MPH

Abstract
IMPORTANCE The level of coronary artery calcium (CAC) can effectively stratify cardiovascular risk
in middle-aged and older adults, but its utility for young adults is unclear.
OBJECTIVES To determine the prevalence of CAC in adults aged 30 to 49 years and the subsequent
association of CAC with coronary heart disease (CHD), cardiovascular disease (CVD), and all-cause
mortality.

Key Points
Question What is the prevalence of
coronary artery calcium (CAC) in adults
aged 30 to 49 years with clinical
indications for CAC scoring, and is CAC
associated with long-term, causespecific mortality in these young adults?
Findings In this cohort study of 22 346

DESIGN, SETTING, AND PARTICIPANTS A multicenter retrospective cohort study was conducted

individuals from the CAC Consortium

among 22 346 individuals from the CAC Consortium who underwent CAC testing (baseline

with clinical indications for CAC, 34.4%

examination, 1991-2010, with follow-up through June 30, 2014; CAC quantified using nonconrast,

had prevalent CAC. The risk of death

cardiac-gated computed tomography scans) for clinical indications and were followed up for cause-

from coronary heart disease,

specific mortality. Participants were free of clinical CVD at baseline. Statistical analysis was performed

cardiovascular disease, or all-cause

from June 1, 2017, to May 31, 2018.

mortality was significantly higher for
those with elevated CAC scores, even

MAIN OUTCOMES AND MEASURES The prevalence of CAC and the subsequent rates of CHD, CVD,
and all-cause mortality. Competing risks regression modeling was used to calculate multivariableadjusted subdistribution hazard ratios for CHD and CVD mortality.

after multivariable adjustment.
Meaning Coronary artery calcium may
potentially be used as a tool to aid
decision-making among select young

RESULTS The sample of 22 346 participants (25.0% women and 75.0% men; mean [SD] age, 43.5
[4.5] years) had a high prevalence of hyperlipidemia (49.6%) and family history of CHD (49.3%) but a
low prevalence of current smoking (11.0%) and diabetes (3.9%). The prevalence of any CAC was
34.4%, with 7.2% having a CAC score of more than 100. During follow-up (mean [SD], 12.7 [4.0]
years), there were 40 deaths related to CHD, 84 deaths related to CVD, and 298 total deaths. A total
of 27 deaths related to CHD (67.5%) occurred among individuals with CAC at baseline. The CHD

adults at elevated lifetime risk for
cardiovascular disease; the relatively
high prevalence of CAC in younger
adults with cardiovascular risk factors
reinforces the need for the adoption of
healthy lifestyle behaviors early in life.

mortality rate per 1000 person-years was 10-fold higher among those with a CAC score of more than
100 (0.69; 95% CI, 0.41-1.16) compared with those with a CAC score of 0 (0.07; 95% CI, 0.04-0.12).
After multivariable adjustment, those with a CAC score of more than 100 had a significantly increased
risk of CHD (subdistribution hazard ratio, 5.6; 95% CI, 2.5-12.7), CVD (subdistribution hazard ratio,
3.3; 95% CI, 1.8-6.2), and all-cause mortality (hazard ratio, 2.6; 95% CI, 1.9-3.6) compared with those
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with a CAC score of 0.
CONCLUSIONS AND RELEVANCE In a large sample of young adults undergoing CAC testing for
clinical indications, 34.4% had CAC, and those with elevated CAC scores had significantly higher rates
of CHD and CVD mortality. Coronary artery calcium may have potential utility for clinical decisionmaking among select young adults at elevated risk of cardiovascular disease.
JAMA Network Open. 2019;2(7):e197440. doi:10.1001/jamanetworkopen.2019.7440

Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(7):e197440. doi:10.1001/jamanetworkopen.2019.7440 (Reprinted)

July 19, 2019

1/12

JAMA Network Open | Cardiology

Association of Coronary Artery Calcium With Long-term, Cause-Specific Mortality Among Young Adults

Introduction
Multiple current cardiovascular guidelines rely on estimates of 10-year absolute risk of cardiovascular
disease (CVD) to guide decisions regarding the allocation of preventive CVD medications.1-4 Coronary
heart disease (CHD) and CVD risk equations are heavily driven by age; as a result, younger adults are
typically estimated to have a low 10-year risk of CVD despite the presence of nonoptimal risk factors
and an elevated lifetime risk of CVD.5 Experts have suggested that earlier treatment for young adults
holds the potential to regress and suppress early atherosclerosis, although who to treat and when
to treat remain unclear.6
Coronary artery calcium (CAC) is a direct marker of atherosclerosis that can robustly stratify risk
for individuals without known CVD,7 allowing it to serve as a tool to aid clinical decision-making
regarding preventive therapies for middle-aged adults.8-12 The utility of CAC in younger populations
is less clear. Prior CAC studies for younger adults have been limited by small sample sizes, a short
duration of follow-up, and a lack of cause-specific mortality.13-15 In response to calls for further
research on this subject,16 we sought to provide data from the CAC Consortium to help determine
what role, if any, CAC may play in the identification of young adults at higher risk for CVD who may be
candidates for more aggressive therapy for CVD prevention.

Methods
Study Design and Study Population
The CAC Consortium is an investigator-initiated, multicenter retrospective cohort comprising 66 636
patients that is aimed at determining the association of CAC with long-term, cause-specific mortality.
The rationale, methods, and baseline results of the cohort have been previously published.17 In brief,
the CAC Consortium consists of patients from 4 high-volume centers from 3 states (California,
Minnesota, and Ohio) with long-standing experience in CAC scoring and with detailed patient data on
demographics, risk factors, and CAC score results. All patients were at least 18 years of age and free
of clinical CVD or cardiovascular symptoms at the time of CAC testing. Participants were screened for
cardiovascular symptoms and excluded if they were symptomatic at baseline. Clinical indications for
CAC testing include individuals with CVD risk factor(s) who are uncertain about their absolute risk of
CVD. Clinical indications were not specifically documented, but most participants underwent CAC
testing owing to either hyperlipidemia or a family history of CVD. Written informed consent for
participation in research was obtained at the individual centers at baseline, and institutional review
board approval for coordinating center activities, including death ascertainment and death
certificate collection, was obtained at Johns Hopkins University School of Medicine. This study
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guidelines for cohort studies.
Baseline data for the CAC Consortium represent the years 1991 through 2010, with follow-up
through June 30, 2014. Comparison of the CAC Consortium with the National Health and Nutrition
Examination Survey 2001-2002, the Multi-Ethnic Study of Atherosclerosis, and the Framingham
Offspring Study have been previously published,17 suggesting comparable baseline characteristics,
use of pharmacotherapy, and mortality rates with these contemporary cohorts. For this study, we
excluded 43 979 patients 50 years or older and 311 patients younger than 30 years, leaving 22 346
for the analysis.

Definition of Cardiovascular Risk Factors
Data on risk factors and laboratory test results were collected as part of the routine clinical visit
associated with the referral for CAC testing and/or from a semistructured in-person interview at the
time of the CAC scan. Hypertension and diabetes were defined by a prior clinical diagnosis or
treatment with antihypertensive therapy or glucose-lowering therapy. Dyslipidemia was defined as a
prior diagnosis of primary hyperlipidemia (low-density lipoprotein cholesterol level >160 mg/dL [to
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convert to millimoles per liter, multiply by 0.0259]), dyslipidemia (elevated triglycerides level >150
mg/dL [to convert to millimoles per liter, multiply by 0.0113] and/or low high-density lipoprotein
cholesterol level <40 mg/dL in men and <50 mg/dL in women [to convert to millimoles per liter,
multiply by 0.0259]), or treatment with any lipid-lowering drug. Smoking was based on self-report
and, for this analysis, was defined as current smoking or no current smoking. Family history of CHD
was predominantly determined by the presence of a first-degree relative with a history of CHD at
any age.
The 10-year risk of atherosclerotic CVD (ASCVD) was calculated according to the Pooled Cohort
Equations (PCE) calculator.1 The PCE is intended for individuals aged 40 to 79 years. For individuals
aged 30 to 39 years, we used the raw PCE equations with removal of the age limitation and
calculated a mean (SD) 10-year risk of 1.1% (1.3%), with a weighted mean 10-year risk of 2.2% (2.0%)
for the entire sample. Lifetime risk of CVD was estimated using the risk algorithm from a previously
published meta-analysis.18
To account for partially missing risk factor data (27.8% of the cohort had missing data, although
most were missing only 1 risk factor), multiple imputation was conducted leveraging nonmissing age,
sex, race/ethnicity, and nonmissing risk factor data and the CAC score. The details of the imputation
method and validation of this approach have previously been described.17 In summary, the validation
of the imputation approach showed nearly identical mean and median ASCVD risk scores and a
robust correlation coefficient of 0.952 between the imputed and directly calculated ASCVD scores.

CAC Testing
Coronary artery calcium was quantified using noncontrast, cardiac-gated computed tomography
scans at each site according to the common standard protocol for each computed tomography
scanner technology. The details of the computed tomography scanners used at each site have been
previously published.17 Coronary artery calcium was quantified for all participants via the Agatston
method, with CAC score categories of 0, 1 to 100, and higher than 100. Coronary artery calcium
scores provide quantification of the total plaque burden in the coronary arteries, with higher scores
indicating a larger burden of plaque and subsequently a higher risk for ASCVD events.

Outcome Ascertainment
The primary outcomes for this study were CHD, CVD, and total mortality during a mean (SD) of 12.7
(4.0) years of follow-up. Mortality was assessed in the CAC Consortium via the linkage of patient
records with the Social Security Administration Death Master File using a previously validated
algorithm.19 The algorithm uses unique patient identifiers in a semiflexible hierarchical matching
process similar to the algorithm used by the National Death Index service. Death certificates were
obtained from the National Death Index service, and the underlying cause of death was categorized
into common causes of death using International Classification of Diseases, Ninth Revision and
International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes
as previously described.17 Internal validation studies against known deaths identified via the
electronic medical record revealed greater than 90% specificity for identifying known deaths, with
sensitivity between 72% and 90%.

Statistical Analysis
Statistical analysis was performed from June 1, 2017, to May 31, 2018. Baseline characteristics are
presented for the total sample and stratified by sex. Proportions are presented for categorical
variables plus means with SDs or medians with interquartile ranges depending on the normality of
the data. χ2 Testing and analysis of variance or Kruskal-Wallis testing were used for formal
comparisons, as appropriate. Absolute mortality rates according to CAC categories are expressed per
1000 person-years. All P values were from 2-sided tests, and results were deemed statistically
significant at P < .05.
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Competing risks regression was used to estimate risk of cause-specific mortality (with
non-CHD–related or non-CVD–related death used as the competing cause); thus, results were
reported as subdistribution hazard ratios with 95% CIs, while Cox proportional hazards regression
was used to estimate hazard ratios for the association between CAC categories and all-cause
mortality. Schoenfeld residuals were used to confirm the proportional hazards assumption, and no
violation was found.
Additional subgroup analyses were performed after stratifying by age, including age groups 30
to 39 years and 40 to 49 years, and lifetime risk, with grouping by optimal or nonoptimal risk factors
(low lifetime risk) and elevated or major risk factors (high lifetime risk) as described by Berry et al.18
All analyses were performed with Stata software, version 14.2 (StataCorp).

Results
Baseline Demographics, CAC Prevalence, and Subsequent Mortality
The baseline characteristics and 10-year estimated ASCVD risk of the 22 346 individuals included in
the study (25.0% women and 75.0% men; mean [SD] age, 43.5 [4.5] years; 12 007 of 13 696
individuals [87.7%] of white race/ethnicity) are shown in Table 1 both for the total sample and
stratified by sex. The prevalence of hyperlipidemia (49.6%) and the prevalence of a family history of
CHD (49.3%) were high, while the prevalence of current smoking (11.0%) and the prevalence of
diabetes (3.9%) were relatively low. The mean (SD) 10-year risk of ASCVD for the total sample was
2.2% (2.0%), with 92.7% of the sample having a 10-year risk of ASCVD of less than 5%.
For the total sample, the prevalence of any CAC was 34.4% (n = 7686; the number needed to
screen to detect any CAC was 3), while 7.2% (n = 1606; the number needed to screen to detect any
CAC was 14) had a CAC score higher than 100 (Table 2). The prevalence of any CAC across the age
range in our study stratified by sex is shown in the eFigure in the Supplement.
During the mean (SD) 12.7 (4.0) years of follow-up (range of maximum follow-up across the 4
sites, 13.6-22.5 years), there were 40 deaths related to CHD, 84 deaths related to CVD, and 298 total
deaths (1.3% of the sample), with an all-cause mortality rate of 1.10 (95% CI, 0.94-1.12) deaths per

Table 1. Baseline Characteristics and Estimated 10-Year CVD Risk Among 22 346 Asymptomatic Individuals
Aged 30 to 49 Years From the CAC Consortium
Individuals, No. (%)
Characteristic

All (N = 22 346)

Women (n = 5576)

Men (n = 16 770)

P Value

Age, mean (SD), y

43.5 (4.5)

44.0 (4.4)

43.3 (4.6)

<.001

White

12 007/13 696 (87.7)

3123/3657 (85.4)

8884/10 039 (88.5)

Asian

591/13 696 (4.3)

181/3657 (4.9)

410/10 039 (4.1)

Black

316/13 696 (2.3)

114/3657 (3.1)

202/10 039 (2.0)

Hispanic

520/13 696 (3.8)

175/3657 (4.8)

345/10 039 (3.4)

Other

198/10 039 (2.0)

Race/ethnicity, No./total No. (%)

<.001

262/13 696 (1.9)

64/3657 (1.8)

Current smoker

2466 (11.0)

646 (11.6)

1820 (10.9)

.13

Hypertension

4496 (20.1)

1045 (18.7)

3451 (20.6)

.003

Hyperlipidemia

11 082 (49.6)

2346 (42.1)

8736 (52.1)

<.001

Diabetes

882 (3.9)

236 (4.2)

646 (3.9)

.21

Family history of CHD

11 006 (49.3)

3123 (56.0)

7883 (47.0)

<.001

CVD risk, mean (SD)
Lifetime

42 (9.0)

34 (7.0)

44 (9.0)

<.001

10 ya

2.2 (2.0)

1.3 (1.3)

2.5 (2.2)

<.001

<5%

20 709 (92.7)

5454 (97.8)

15 255 (91.0)

5%-7.5%

1049 (4.7)

90 (1.6)

959 (5.7)

>7.5%

588 (2.6)

32 (0.6)

556 (3.3)

10-y categories
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The 10-year risk was calculated using the Pooled
Cohort Equations.
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1000 person-years (Table 2). The top 2 causes of death were cancer (86 [28.9%]) and CVD (84
[28.2%]). The rate of all-cause mortality was similar between the sexes (women, 0.96; 95% CI, 0.751.21; men, 1.10; 95% CI, 0.95-1.20; P = .35), while men had higher rates than women of CVD mortality
(0.34; 95% CI, 0.27-0.42 vs 0.17; 95% CI, 0.10-0.31; P = .03) and CHD mortality (0.18; 95% CI, 0.130.24 vs 0.03; 95% CI, 0.01-0.12; P = .004).
The prevalence of traditional CVD risk factors and subsequent mortality rates according to
baseline CAC scores are shown in Table 3. The prevalence for each of the 5 traditional risk factors
(hypertension, hyperlipidemia, current smoking, family history of CHD, and diabetes) was
significantly increased in those with a CAC score of more than 100 compared with those with a CAC
score of 0. However, 662 of the 1606 individuals (41.2%) with a CAC score higher than 100 had 0 or 1
traditional risk factors. The rate of CHD mortality per 1000 person-years was 4-fold higher among
individuals with any CAC (0.27 CHD-related deaths per 1000 person-years; 95% CI, 0.19-0.40) and
10-fold higher among individuals with a CAC score higher than 100 (0.69 CHD-related deaths per
1000 person-years; 95% CI, 0.41-1.16) compared with individuals with a CAC score of 0 (0.07
CHD-related deaths per 1000 person-years; 95% CI, 0.04-0.12). A total of 27 of 40 CHD-related
deaths (67.5%) occurred among individuals with CAC at baseline.
Subdistribution hazard ratios for CHD and CVD and hazard ratios for all-cause mortality
according to subgroups of CAC are shown in Table 4. After adjustment for traditional risk factors, the
risk of death due to CHD remained significantly increased among individuals with a CAC score higher
than 100 compared with those with a CAC score of 0 (subdistribution hazard ratio, 5.6; 95% CI,
2.5-12.7), as did the risk of CVD mortality (subdistribution hazard ratio, 3.3; 95% CI, 1.8-6.2) and
all-cause mortality (hazard ratio, 2.6; 95% CI, 1.9-3.6).
Of the 22 346 individuals in our sample, 14 233 (63.7%) were found to have elevated and/or
major CVD risk factors and were categorized as having a high lifetime risk for CVD. Of the 40 deaths
related to CHD during follow-up, 34 (85.0%) occurred among individuals with an elevated lifetime
risk for CVD. After multivariable adjustment, a significant association remained between CAC and the
risk for CHD, CVD, and all-cause mortality among individuals with a high lifetime risk for CVD (eTable
in the Supplement). A similar association was seen between CAC and mortality risk among individuals
with a low lifetime risk for CVD, although the association between CAC and CHD risk did not reach
statistical significance, likely owing to the low number of CHD-related deaths in this group.

Table 2. Prevalence of CAC and Subsequent Mortality Among 22 346 Asymptomatic Individuals
Aged 30 to 49 Years From the CAC Consortium
Variable

All (N = 22 346)

Women (n = 5576)

Men (n = 16 770)

0

14 660 (65.6)

4613 (82.7)

10 047 (59.9)

1-100

6080 (27.2)

831 (14.9)

5249 (31.3)

>100

1606 (7.2)

132 (2.4)

1474 (8.8)

P Value

CAC prevalence, No. (%)a

<.001

CHD-related death
No. (%)

40 (0.2)

2 (0.04)

38 (0.2)

.004

Rate (95% CI)b

0.14 (0.10-0.19)

0.03 (0.01-0.12)

0.18 (0.13-0.24)

.004

CVD-related death
No. (%)

84 (0.4)

12 (0.2)

72 (0.4)

.02

Rate (95% CI)b

0.30 (0.24-0.37)

0.17 (0.10-0.31)

0.34 (0.27-0.42)

.03

All-cause death
No. (%)

298 (1.3)

66 (1.1)

232 (1.4)

.26

Rate (95% CI)b

1.10 (0.94-1.12)

0.96 (0.75-1.21)

1.10 (0.95-1.20)

.35
Abbreviations: CAC, coronary artery calcium; CHD,
coronary heart disease; CVD, cardiovascular disease.

Cause of death, No./total No. (%)
Neoplasms

86/298 (28.9)

33/66 (50.0)

53/232 (22.8)

CVD

84/298 (28.2)

12/66 (18.2)

72/232 (31.0)

Injury and poisoning

42/298 (14.6)

6/66 (9.1)

36/232 (15.5)

JAMA Network Open. 2019;2(7):e197440. doi:10.1001/jamanetworkopen.2019.7440 (Reprinted)

a

The CAC prevalence was categorized according to
Agatston scores of 0, 1 to 100, and higher than 100.

b

Rate per 1000 person-years.

.001
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Finally, to further refine our results by baseline age, we conducted additional analyses
stratifying by age groups of 30 to 39 years and 40 to 49 years (Figure). The prevalence of CAC was
significantly higher in individuals aged 40 to 49 years compared with those aged 30 to 39 years, with
29.3% of individuals aged 40 to 49 years having a CAC score of 1 to 100 and 8.4% of individuals aged
40 to 49 years having a CAC score higher than 100 and with 19.1% of individuals aged 30 to 39 years
having a CAC score of 1 to 100 and 2.7% of individuals aged 30 to 39 years having a CAC score of
more than 100. There was a graded increase in CHD, CVD, and all-cause mortality across increasing
CAC strata for individuals aged 30 to 39 years and for those aged 40 to 49 years. Although

Table 3. Prevalence of Traditional CVD Risk Factors and Subsequent Mortality According to Baseline CAC Score
Among 22 346 Asymptomatic Individuals Aged 30 to 49 Years From the CAC Consortium
Individuals, No. (%)
CVD Risk Factor

CAC Score = 0
(n = 14 660 [65.6%])a

CAC Score = 1-100
(n = 6080 [27.2%])

CAC Score >100
(n = 1606 [7.2%])

P Value

Hypertension

2567 (17.5)

1435 (23.6)

494 (30.8)

<.001

Hyperlipidemia

6684 (45.6)

3401 (55.9)

997 (62.1)

<.001

Current smoker

1521 (10.4)

706 (11.6)

239 (14.9)

<.001

Family history of CHD

6947 (47.4)

3150 (51.8)

909 (56.6)

<.001

Diabetes

450 (3.1)

296 (4.9)

136 (8.5)

<.001

0

3389 (23.1)

975 (16.0)

176 (11.0)

1

5819 (39.7)

2204 (36.3)

486 (30.3)

≥2

4159 (28.4)

2040 (33.6)

605 (37.7)

Total No. of risk factors

<.001

Mortality
CHD-related death
No. (%)

13 (0.09)

13 (0.2)

14 (0.9)

Rate (95% CI)b

0.07 (0.04-0.12)

0.17 (0.10-0.29)

0.69 (0.41-1.16)

<.001

CVD-related death
No. (%)

36 (0.2)

28 (0.5)

20 (1.2)

Rate (95% CI)b

0.20 (0.14-0.27)

0.36 (0.25-0.52)

0.98 (0.63-1.51)

<.001

No. (%)

151 (1.0)

90 (1.5)

57 (3.5)

Rate (95% CI)b

0.82 (0.70-0.96)

1.23 (0.94-1.40)

2.81 (2.22-3.63)

Abbreviations: CAC, coronary artery calcium; CHD,
coronary heart disease; CVD, cardiovascular disease.

All-cause death

a

The CAC prevalence was categorized according to
Agatston scores of 0, 1 to 100, and higher than 100.

b

Rate per 1000 person-years.

<.001

Table 4. Subdistribution Hazard Ratios for CHD and CVD and Hazard Ratios for All-Cause Mortality
Among 22 346 Asymptomatic Individuals Aged 30 to 49 Years From the CAC Consortium
Hazard Ratio (95% CI)
CAC Prevalencea

Unadjusted

Model 1b

Model 2c

CHD mortality
CAC score
0

1 [Reference]

1 [Reference]

1 [Reference]

1-100

2.4 (1.1-5.1)

2.0 (0.9-4.4)

1.7 (0.8-3.9)

>100

9.7 (4.5-20.6)

7.8 (3.4-17.9)

5.6 (2.5-12.7)

CVD mortality
CAC score
0

1 [Reference]

1 [Reference]

1 [Reference]

1-100

1.8 (1.1-3.0)

1.7 (1.0-2.9)

1.5 (0.9-2.5)

>100

5.0 (2.9-8.7)

4.5 (2.5-8.4)

3.3 (1.8-6.2)

All-cause mortality

Abbreviations: CAC, coronary artery calcium; CHD,
coronary heart disease; CVD, cardiovascular disease.
a

The CAC prevalence was categorized according to
Agatston scores of 0, 1 to 100, and higher than 100.

b

Adjusted for age and sex.

c

Adjusted for age, sex, hyperlipidemia, hypertension,
smoking, diabetes, and a family history of CHD.

CAC score
0

1 [Reference]

1 [Reference]

1 [Reference]

1-100

1.4 (1.1-1.8)

1.4 (1.0-1.8)

1.2 (0.9-1.6)

>100

3.4 (2.5-4.7)

3.1 (2.3-4.3)

2.6 (1.9-3.6)
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individuals aged 30 to 39 years were less likely to have CAC, mortality rates for those with a CAC
score higher than 100 appeared to be similar between those aged 30 to 39 years and those aged 40
to 49 years.

Discussion
In a large, multicenter cohort with long-term follow-up of adults aged 30 to 49 years undergoing CAC
testing for clinical indications, we found that 34.4% of the sample had any CAC and that 7.2% had
significantly elevated CAC scores (>100). Subsequent rates of CHD, CVD, and total mortality were
significantly elevated among individuals with elevated CAC, with 67.5% of all future CHD-related
deaths occurring among those with any baseline CAC. After multivariable adjustment, there was
more than a 5-fold increase in risk for CHD mortality and a 3-fold increase in risk for CVD mortality
among individuals with a CAC score higher than 100 compared with those with a CAC score of 0. The
high prevalence of premature coronary atherosclerosis in this sample of younger adults highlights
the need to increase focus on the importance of adopting healthy lifestyle behaviors early in life. In
addition, these findings suggest that CAC testing could potentially be considered for further risk
stratification in select young adults with elevated cardiovascular risk.

Comparisons With Prior Data
In general, data on CAC in young adults are limited. A prior study from a separate referral-based
cohort found that, among 8143 individuals younger than 45 years at the time of CAC screening (mean

Figure. Prevalence of Coronary Artery Calcium (CAC) and Subsequent Rates of Coronary Heart Disease (CHD),
Cardiovascular Disease (CVD), and All-Cause Mortality Among Young Adults
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age, 40 years), approximately 30% had CAC, and the risk of all-cause mortality increased across
categories of CAC.15 The study was limited by a short duration of follow-up (mean, 5.8 years) and a
lack of cause-specific mortality. Our results found a similar graded increase in rates of all-cause
mortality across categories of CAC, although our overall mortality rates were lower, potentially owing
to the more contemporary nature of our data and the lower population rates of CHD- and
CVD-related deaths compared with data from prior decades.20
A recent analysis from the community-based Coronary Artery Risk Development in Young
Adults (CARDIA) prospective cohort study found that approximately 10% of the 3043 CARDIA
participants aged 32 to 46 years (mean age, 40.3 years) had any CAC and that those individuals had
a subsequent 5-fold higher risk for incident CHD events and a 3-fold higher risk for incident CVD
events during 12.5 years of follow-up.14 The CARDIA study was limited by a relatively small sample
size with very few CHD- and CVD-related deaths but did demonstrate that even low CAC scores
among young adults are associated with a higher risk of CHD and CVD by middle age, suggesting that
any CAC is abnormal in this age range. Compared with the CARDIA study, we found a higher
prevalence of CAC (34.4% vs 10%), likely owing to the presence of clinical indications for CAC scoring
and therefore a high prevalence of elevated lifetime risk for CVD as opposed to a general community
representative sample. However, in comparison with the hazard ratios for incident CHD and CVD
events in the CARDIA study,14 we found a comparable 5-fold higher likelihood of CHD mortality and
3-fold higher likelihood of CVD mortality in those with elevated CAC.

Determinants of Premature CAC
Although age is the dominant factor associated with the development of CAC, multiple traditional
risk factors and lifestyle behaviors have been associated with the development of premature CAC.
Prior data from CARDIA demonstrated that baseline level of low-density lipoprotein cholesterol,
cigarette smoking, systolic blood pressure, and blood glucose level in participants at baseline (aged
18-30 years) all were independently correlated with the likelihood of subsequent CAC 15 years later.21
In addition, higher intake of fruits and vegetables, high levels of cardiorespiratory fitness, and lack of
abdominal obesity have been associated with a lower likelihood of premature CAC.22-24
Accordingly, our data demonstrated a higher likelihood of CAC across all traditional CVD risk
factors, and the prevalence of CAC increased as the burden of risk factors increased. Despite this
finding, more than 40% of those with a CAC score higher than 100 had 0 or 1 reported CVD risk
factor. More important, prior research has shown that individuals with CAC but no traditional CVD
risk factors are at significantly elevated risk for CHD events compared with those with traditional risk
factors but no CAC.25

CAC Testing Among Younger Adults
The recent 2018 cholesterol guidelines from the American Heart Association and the American
College of Cardiology recommend CAC scoring for intermediate-risk (10-year CVD risk, ⱖ7.5% to
<20%) individuals who are uncertain about their decision to start statin therapy.26 Prior analyses
have suggested that, for individuals who are uncertain about statin use, CAC testing may be the best
option to determine the magnitude of the potential benefit from statin therapy.9,10 In addition, CAC
scoring has been proposed to help determine an individual’s likelihood of benefit from aspirin as well
as antihypertensive therapy.11,12
Our data suggest that the clinical utility of CAC testing may extend to select younger adults,
mainly those at elevated lifetime risk for CVD and uncertainty regarding treatment decisions. Even
for individuals in their 30s, despite their young age, approximately 1 in 5 had CAC. Women were less
likely to have CAC; therefore, CAC scoring for young women should be considered cautiously given
the low likelihood of a positive finding. However, given the exponential nature of CAC progression,14
the presumed high lifetime risk of individuals with CAC, and the general safety and inexpensive
nature of most preventive medications, considering tailored preventive pharmacotherapy in the
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context of a clinician-patient risk discussion appears reasonable for young men and women with
any CAC.
A CAC score of 0 has been repeatedly shown to be associated with very low risk for CHD and
CVD events.27,28 For young adults at elevated lifetime risk, a CAC score of 0 does not lessen the
importance of heart-healthy lifestyle behaviors, but given that many patients would prefer to avoid
preventive medications, the potential for CAC testing to identify patients for whom lifestyle therapies
can be favored instead of preventive medications remains an important patient-centered outcome.

Strengths and Limitations
Our analysis benefited from data from multiple experienced centers geographically dispersed
throughout the United States with a large sample size of both men and women with long-term
follow-up. In addition, the ability to analyze the association of CAC with cause-specific mortality
during 12 years of follow-up is novel, and the large sample size allowed subgroup analyses by age, sex,
and lifetime risk.
Referral bias is a potential limitation, and generalizability must be interpreted in the appropriate
context. The exact clinical indications for CAC scoring were not documented, although most
participants underwent CAC scoring owing to the presence of a major CVD risk factor (mainly
hyperlipidemia or a family history of CVD) or multiple CVD risk factors. However, as opposed to
general screening, most experts recommend CAC testing as a tool for clinical decision-making as part
of a sequential process of risk assessment.29
Therefore, our results, which represent the prevalence and outcomes associated with CAC
among younger individuals with clinical indications for CAC scoring, remain clinically relevant. There
were individuals in our analysis with missing data, but most were missing only 1 risk factor, and there
was excellent correlation between mean and median ASCVD risk scores calculated directly compared
with scores calculated using imputed data.
Other limitations include self-reporting of risk factors and the inadequacies of vital status
ascertainment in the United States, with a potential for up to 10% underestimation of mortality,30
although this underestimation would be expected to be nondifferential across CAC groups. We used
the PCE to get a general sense of the estimated 10-year cardiovascular risk in our sample, although
the American Heart Association and American College of Cardiology guidelines are clear that there
are no data to support the use of the PCE for individuals younger than 40 years. Also, 87.7% of our
study sample was of white race/ethnicity, and we were unable to examine associations specifically
among nonwhite races/ethnicities.

Conclusions
In a large, multicenter cohort of young adults with long-term follow-up, CAC was not uncommon,
with elevated CAC scores independently associated with higher rates of CHD, CVD, and all-cause
mortality. For younger individuals with low 10-year risk of ASCVD but with other risk indicators, CAC
scoring may provide a method for further risk assessment to help guide the intensity of preventive
interventions.

ARTICLE INFORMATION
Accepted for Publication: May 29, 2019.
Published: July 19, 2019. doi:10.1001/jamanetworkopen.2019.7440
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Miedema MD
et al. JAMA Network Open.
Corresponding Author: Michael D. Miedema, MD, MPH, Minneapolis Heart Institute Foundation, 920 E 28th St,
Ste 600, Minneapolis, MN 55414 (mdm307@mail.harvard.edu).
Author Affiliations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota (Miedema, Knickelbine,
JAMA Network Open. 2019;2(7):e197440. doi:10.1001/jamanetworkopen.2019.7440 (Reprinted)

July 19, 2019

9/12

JAMA Network Open | Cardiology

Association of Coronary Artery Calcium With Long-term, Cause-Specific Mortality Among Young Adults

Oberembt); Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of
Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland (Dardari, Michos, Blaha); Center for Prevention
and Wellness Research, Baptist Health Medical Group, Miami Beach, Florida (Nasir); Department of Medicine,
Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts (Blankstein); Department of
Radiology, Brigham and Women’s Hospital, Boston, Massachusetts (Blankstein); Department of Radiology, Weill
Cornell Medical College, New York, New York (Shaw); Department of Cardiac Imaging, The Princeton Longevity
Center, Princeton, New Jersey (Rumberger); Department of Medicine, Mount Sinai, New York, New York
(Rozanski); Department of Imaging, Smidt Heart Institute, Cedars-Sinai, Los Angeles, California (Berman);
Department of Medicine, Smidt Heart Institute, Cedars-Sinai, Los Angeles, California (Berman); Los Angeles
BioMedical Research Institute, Harbor University of California Los Angeles Medical Center, Torrance (Budoff).
Author Contributions: Dr Miedema and Ms Dardari had full access to all the data in the study and take
responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Miedema, Dardari, Blankstein, Knickelbine, Oberembt, Shaw, Berman, Blaha.
Acquisition, analysis, or interpretation of data: Miedema, Dardari, Nasir, Blankstein, Shaw, Rumberger, Michos,
Rozanski, Berman, Budoff, Blaha.
Drafting of the manuscript: Miedema, Shaw.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Miedema, Dardari, Shaw, Blaha.
Obtained funding: Rumberger, Blaha.
Administrative, technical, or material support: Oberembt, Budoff, Blaha.
Supervision: Nasir, Blankstein, Shaw, Rumberger, Berman, Blaha.
Conflict of Interest Disclosures: Dr Blankstein reported receiving grants from Astellas Inc and grants and personal
fees from Amgen Inc outside the submitted work and serving on the board of directors for the Society of
Cardiovascular Computed Tomography and the board of directors for the American Society of Preventive
Cardiology. Dr Budoff reported receiving grants from General Electric during the conduct of the study. Dr Blaha
reported receiving grants and personal fees from Amgen; grants from Sanofi and the American Heart Association;
and personal fees from Novo Nordisk, Bayer, and Novartis outside the submitted work. No other disclosures were
reported.
Funding/Support: Dr Blaha received support from National Institutes of Health award L30 HL110027.
Role of the Sponsor: The funding source assisted with the design and conduct of the study but had no role in the
collection, management, analysis, and interpretation of the data; preparation, review, or approval of the
manuscript; and decision to submit the manuscript for publication.
Additional Information: The data that support the findings of this study are available from Dr Blaha on
reasonable request.
REFERENCES
1. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25, pt B):2889-2934. doi:10.1016/j.jacc.
2013.11.002
2. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Statin use for the primary
prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement.
JAMA. 2016;316(19):1997-2007. doi:10.1001/jama.2016.15450
3. Bibbins-Domingo K; US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular
disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med.
2016;164(12):836-845. doi:10.7326/M16-0577
4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive
summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066
5. Singh A, Collins BL, Gupta A, et al. Cardiovascular risk and statin eligibility of young adults after an MI: Partners
YOUNG-MI Registry. J Am Coll Cardiol. 2018;71(3):292-302. doi:10.1016/j.jacc.2017.11.007
6. Robinson JG, Gidding SS. Curing atherosclerosis should be the next major cardiovascular prevention goal. J Am
Coll Cardiol. 2014;63(25, pt A):2779-2785. doi:10.1016/j.jacc.2014.04.009

JAMA Network Open. 2019;2(7):e197440. doi:10.1001/jamanetworkopen.2019.7440 (Reprinted)

July 19, 2019

10/12

JAMA Network Open | Cardiology

Association of Coronary Artery Calcium With Long-term, Cause-Specific Mortality Among Young Adults

7. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic
groups. N Engl J Med. 2008;358(13):1336-1345. doi:10.1056/NEJMoa072100
8. Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for
coronary heart disease prediction. JAMA. 2010;303(16):1610-1616. doi:10.1001/jama.2010.461
9. Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular
disease risk assessment. J Am Coll Cardiol. 2016;67(2):139-147. doi:10.1016/j.jacc.2015.10.058
10. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin
candidates according to American College of Cardiology/American Heart Association cholesterol management
guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657-1668. doi:10.1016/j.
jacc.2015.07.066
11. Miedema MD, Duprez DA, Misialek JR, et al. Use of coronary artery calcium testing to guide aspirin utilization
for primary prevention: estimates from the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Qual Outcomes.
2014;7(3):453-460. doi:10.1161/CIRCOUTCOMES.113.000690
12. McEvoy JW, Martin SS, Dardari ZA, et al. Coronary artery calcium to guide a personalized risk-based approach
to initiation and intensification of antihypertensive therapy. Circulation. 2017;135(2):153-165. doi:10.1161/
CIRCULATIONAHA.116.025471
13. Paixao AR, Ayers CR, El Sabbagh A, et al. Coronary artery calcium improves risk classification in younger
populations. JACC Cardiovasc Imaging. 2015;8(11):1285-1293. doi:10.1016/j.jcmg.2015.06.015
14. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with
incident coronary heart disease and death. JAMA Cardiol. 2017;2(4):391-399. doi:10.1001/jamacardio.2016.5493
15. Tota-Maharaj R, Blaha MJ, McEvoy JW, et al. Coronary artery calcium for the prediction of mortality in young
adults <45 years old and elderly adults >75 years old. Eur Heart J. 2012;33(23):2955-2962. doi:10.1093/eurheartj/
ehs230
16. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the
American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;
129(25)(suppl 2):S49-S73. doi:10.1161/01.cir.0000437741.48606.98
17. Blaha MJ, Whelton SP, Al Rifai M, et al. Rationale and design of the Coronary Artery Calcium Consortium:
a multicenter cohort study. J Cardiovasc Comput Tomogr. 2017;11(1):54-61. doi:10.1016/j.jcct.2016.11.004
18. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321-329. doi:
10.1056/NEJMoa1012848
19. Al-Mallah MH, Keteyian SJ, Brawner CA, Whelton S, Blaha MJ. Rationale and design of the Henry Ford Exercise
Testing Project (the FIT Project). Clin Cardiol. 2014;37(8):456-461. doi:10.1002/clc.22302
20. Benjamin EJ, Virani SS, Callaway CW, et al; American Heart Association Council on Epidemiology and
Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018
update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492. doi:10.1161/CIR.
0000000000000558
21. Loria CM, Liu K, Lewis CE, et al. Early adult risk factor levels and subsequent coronary artery calcification: the
CARDIA Study. J Am Coll Cardiol. 2007;49(20):2013-2020. doi:10.1016/j.jacc.2007.03.009
22. Miedema MD, Petrone A, Shikany JM, et al. Association of fruit and vegetable consumption during early
adulthood with the prevalence of coronary artery calcium after 20 years of follow-up: the Coronary Artery Risk
Development in Young Adults (CARDIA) Study. Circulation. 2015;132(21):1990-1998. doi:10.1161/
CIRCULATIONAHA.114.012562
23. Lee CD, Jacobs DR Jr, Hankinson A, Iribarren C, Sidney S. Cardiorespiratory fitness and coronary artery
calcification in young adults: the CARDIA Study. Atherosclerosis. 2009;203(1):263-268. doi:10.1016/j.
atherosclerosis.2008.06.012
24. Reis JP, Loria CM, Lewis CE, et al. Association between duration of overall and abdominal obesity beginning in
young adulthood and coronary artery calcification in middle age. JAMA. 2013;310(3):280-288. doi:10.1001/jama.
2013.7833
25. Silverman MG, Blaha MJ, Krumholz HM, et al. Impact of coronary artery calcium on coronary heart disease
events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis.
Eur Heart J. 2014;35(33):2232-2241. doi:10.1093/eurheartj/eht508

JAMA Network Open. 2019;2(7):e197440. doi:10.1001/jamanetworkopen.2019.7440 (Reprinted)

July 19, 2019

11/12

JAMA Network Open | Cardiology

Association of Coronary Artery Calcium With Long-term, Cause-Specific Mortality Among Young Adults

26. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/
PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College
of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73
(24):3168-3209. doi:10.1016/j.jacc.2018.11.002
27. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other
negative risk markers for cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation.
2016;133(9):849-858. doi:10.1161/CIRCULATIONAHA.115.018524
28. Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic
cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J. 2018;39
(25):2401-2408. doi:10.1093/eurheartj/ehy217
29. Lloyd-Jones DM. Coronary artery calcium scoring: are we there yet? J Am Coll Cardiol. 2015;66(15):1654-1656.
doi:10.1016/j.jacc.2015.08.031
30. da Graca B, Filardo G, Nicewander D. Consequences for healthcare quality and research of the exclusion of
records from the Death Master File. Circ Cardiovasc Qual Outcomes. 2013;6(1):124-128. doi:10.1161/
CIRCOUTCOMES.112.968826
SUPPLEMENT.
eTable. Subdistribution Hazard Ratios for CHD and CVD Death and Hazard Ratios for All-Cause Mortality According
to CAC in 22 346 Individuals age 30-49 Years Stratified by Lifetime Risk of CVD
eFigure. The Prevalence of CAC According to Age Stratified by Sex

JAMA Network Open. 2019;2(7):e197440. doi:10.1001/jamanetworkopen.2019.7440 (Reprinted)

July 19, 2019

12/12

